News & Updates

Nirmatrelvir-ritonavir benefits persist against COVID
Nirmatrelvir-ritonavir benefits persist against COVID
07 Nov 2023 byElvira Manzano

Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options. 

Nirmatrelvir-ritonavir benefits persist against COVID
07 Nov 2023
Cefazolin beneficial in infective endocarditis caused by methicillin-susceptible S aureus
Cefazolin beneficial in infective endocarditis caused by methicillin-susceptible S aureus
06 Nov 2023
Histologic inflammation of IBD a risk factor for serious infections
Histologic inflammation of IBD a risk factor for serious infections
03 Nov 2023

Among individuals with inflammatory bowel disease (IBD), histologic inflammation appears to contribute to an increased risk of serious infections such as sepsis, according to a study, suggesting that achieving remission may reduce infections in IBD.

Histologic inflammation of IBD a risk factor for serious infections
03 Nov 2023
Antiviral therapy safe, effective in children with immune-tolerant HBV infection
Antiviral therapy safe, effective in children with immune-tolerant HBV infection
28 Oct 2023